Miyazawa T, Yamakido M, Ikeda S, Furukawa K, Takiguchi Y, Tada H, Shirakusa T
Department of Pulmonary Medicine, Hiroshima City Hospital, Hiroshima, Japan.
Chest. 2000 Oct;118(4):959-65. doi: 10.1378/chest.118.4.959.
To assess the uncovered Ultraflex nitinol stent (Boston Scientific; Natick, MA) for its efficacy and safety.
DESIGN, SETTING, AND PATIENTS: Between October 1997 and October 1998, we carried out a prospective multicenter study at six hospitals in Japan. Fifty-four Ultraflex stents were inserted in 34 patients with inoperable malignant airway stenosis using a flexible and/or a rigid bronchoscope under fluoroscopic and endoscopic visualization.
Clinical, endoscopic examination, and pulmonary function on days 1, 30, and 60 after stent implantation showed improvement. In 19 patients (56%), stent implantation was performed as an emergency procedure because of life-threatening tracheobronchial obstruction. Immediate relief of dyspnea was achieved in 82% of the patients. The dyspnea index improved significantly after implantation (before vs. days 1, 30, and 60; p<0.001). Significant improvements were observed in obstruction of airway diameter (81+/-15% before vs. 14+/-17% on day 1, 12+/-12% on day 30, and 22+/-28% on day 60; p<0.001). Vital capacity (VC), FEV(1), and peak expiratory flow (PEF) increased significantly after stent implantation: before vs immediately after VC (p<0.01), FEV(1) (p<0.001), and PEF (p<0.05). The main complications were tumor ingrowth (24%) and tumor overgrowth (21%). After coagulation with an Nd-YAG laser or argon plasma coagulation, mechanical coring out using the bevel of a rigid bronchoscope was necessary in patients showing tumor ingrowth or overgrowth. Removal and reposition were possible in case of misplacement. There were no problems with migration and retained secretions. The median survival time of patients was 3 months. The 1-year survival rate was 25.4%.
In this study of the Ultraflex nitinol stent, we have demonstrated that patients were relieved from dyspnea, which contributed to improved quality of life, with minimal complications. This stent can be used safely, even in the subglottic region. Owing to its excellent flexibility and biocompatibility, the stent is also indicated in certain complicated situations, eg, narrow stenosis, hourglass stenosis, curvilinear stenosis, bilateral mainstem bronchial stenoses, and long stenosis of varying diameters.
评估未覆盖的Ultraflex镍钛合金支架(波士顿科学公司;马萨诸塞州纳蒂克)的疗效和安全性。
设计、地点和患者:1997年10月至1998年10月期间,我们在日本的六家医院进行了一项前瞻性多中心研究。在透视和内镜直视下,使用柔性和/或刚性支气管镜,将54个Ultraflex支架植入34例无法手术的恶性气道狭窄患者体内。
支架植入后第1天、30天和60天的临床、内镜检查及肺功能均有改善。19例患者(56%)因危及生命的气管支气管阻塞而进行了紧急支架植入手术。82%的患者呼吸困难立即得到缓解。植入后呼吸困难指数显著改善(术前与第1天、30天和60天相比;p<0.001)。气道直径阻塞情况有显著改善(术前为81±15%,第1天为14±17%,第30天为12±12%,第60天为22±28%;p<0.001)。支架植入后肺活量(VC)、第1秒用力呼气容积(FEV₁)和呼气峰值流速(PEF)显著增加:术前与术后即刻相比,VC(p<0.01)、FEV₁(p<0.001)和PEF(p<于0.05)。主要并发症为肿瘤长入(24%)和肿瘤过度生长(21%)。对于出现肿瘤长入或过度生长的患者,在使用钕钇铝石榴石激光或氩等离子体凝固后,需要使用刚性支气管镜的斜面进行机械去核。如果发生移位,可以进行取出和重新定位。没有出现支架移位和分泌物潴留的问题。患者的中位生存时间为3个月。1年生存率为25.4%。
在这项关于Ultraflex镍钛合金支架的研究中,我们证明患者的呼吸困难得到缓解,这有助于提高生活质量,且并发症极少。这种支架即使在声门下区域也可安全使用。由于其出色的柔韧性和生物相容性,该支架也适用于某些复杂情况,如狭窄狭窄、沙漏形狭窄、曲线形狭窄、双侧主支气管狭窄以及不同直径的长段狭窄。